Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) Plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) Versus Bevacizumab Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/23/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) Plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) Versus Bevacizumab Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/23/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) Plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) Versus Bevacizumab Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/23/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) Plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) Versus Bevacizumab Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/23/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) Plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) Versus Bevacizumab Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Bahia Blanca,
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) Plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) Versus Bevacizumab Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Bahia Blanca,
Click here to add this to my saved trials
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer
Status: Enrolling
Updated:  9/28/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer
Status: Enrolling
Updated: 9/28/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer
The Role of TAB3 Protein in Tumorigenesis
Status: Enrolling
Updated:  9/28/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer
The Role of TAB3 Protein in Tumorigenesis
Status: Enrolling
Updated: 9/28/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux ) in EGFR Expressing Metastatic Colorectal Cancer (CRC)
Status: Enrolling
Updated:  9/29/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux ) in EGFR Expressing Metastatic Colorectal Cancer (CRC)
Status: Enrolling
Updated: 9/29/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors
Status: Enrolling
Updated:  9/29/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors
Status: Enrolling
Updated: 9/29/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan
A Phase II Study of High Dose Cetuximab Plus Irinotecan in Colorectal Cancer Patients With KRS-Wild Type Tumors Who Progressed After Failure of Prior Standard Dose ofCetuximab Plus Irinotecan
Status: Enrolling
Updated:  9/29/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan
A Phase II Study of High Dose Cetuximab Plus Irinotecan in Colorectal Cancer Patients With KRS-Wild Type Tumors Who Progressed After Failure of Prior Standard Dose ofCetuximab Plus Irinotecan
Status: Enrolling
Updated: 9/29/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
Pilot Study of the Combination of MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor, in Patients With Advanced Colorectal Carcinoma
Status: Enrolling
Updated:  9/29/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
Pilot Study of the Combination of MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor, in Patients With Advanced Colorectal Carcinoma
Status: Enrolling
Updated: 9/29/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Latino Peers as Patient Navigators for Colon Cancer Screening
Training Latinos as Peer Patient Navigators for Colon Cancer Screening
Status: Enrolling
Updated:  9/29/2015
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Latino Peers as Patient Navigators for Colon Cancer Screening
Training Latinos as Peer Patient Navigators for Colon Cancer Screening
Status: Enrolling
Updated: 9/29/2015
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Psychosocial Adjustment After Radiation Therapy in Patients With Cancer
Psychosocial Adjustment During the Post-Radiation Treatment Transition
Status: Enrolling
Updated:  9/29/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Psychosocial Adjustment After Radiation Therapy in Patients With Cancer
Psychosocial Adjustment During the Post-Radiation Treatment Transition
Status: Enrolling
Updated: 9/29/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Comparing Two Types of Swabs in Collecting Cell Samples for Anal Pap Tests and Human Papillomavirus Tests in Men Who Have Sex With Men
Comparison of Flocked vs. Dacron Swab for Anal Cytology, Correspondence With High Resolution Anoscopy
Status: Enrolling
Updated:  9/30/2015
UCLA
mi
from
Los Angeles, CA
Comparing Two Types of Swabs in Collecting Cell Samples for Anal Pap Tests and Human Papillomavirus Tests in Men Who Have Sex With Men
Comparison of Flocked vs. Dacron Swab for Anal Cytology, Correspondence With High Resolution Anoscopy
Status: Enrolling
Updated: 9/30/2015
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer
Phase I/II Trial to Evaluate Ethyol as a Protective Agent for Irinotecan (CPT-11) Toxicities in Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated:  9/30/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer
Phase I/II Trial to Evaluate Ethyol as a Protective Agent for Irinotecan (CPT-11) Toxicities in Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated: 9/30/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer
Phase I/II Trial to Evaluate Ethyol as a Protective Agent for Irinotecan (CPT-11) Toxicities in Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated:  9/30/2015
Wilshire Oncology Medical Group
mi
from
Rancho Cucamonga, CA
Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer
Phase I/II Trial to Evaluate Ethyol as a Protective Agent for Irinotecan (CPT-11) Toxicities in Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated: 9/30/2015
Wilshire Oncology Medical Group
mi
from
Rancho Cucamonga, CA
Click here to add this to my saved trials
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies
Status: Enrolling
Updated:  9/30/2015
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies
Status: Enrolling
Updated: 9/30/2015
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies
Status: Enrolling
Updated:  9/30/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies
Status: Enrolling
Updated: 9/30/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer
The Vulnerable Elders Survey Study of Older Cancer Patients
Status: Enrolling
Updated:  10/1/2015
Uh-Luicc
mi
from
Mentor, OH
Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer
The Vulnerable Elders Survey Study of Older Cancer Patients
Status: Enrolling
Updated: 10/1/2015
Uh-Luicc
mi
from
Mentor, OH
Click here to add this to my saved trials
Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer
The Vulnerable Elders Survey Study of Older Cancer Patients
Status: Enrolling
Updated:  10/1/2015
UH-Green Road
mi
from
South Euclid, OH
Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer
The Vulnerable Elders Survey Study of Older Cancer Patients
Status: Enrolling
Updated: 10/1/2015
UH-Green Road
mi
from
South Euclid, OH
Click here to add this to my saved trials
Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer
The Vulnerable Elders Survey Study of Older Cancer Patients
Status: Enrolling
Updated:  10/1/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer
The Vulnerable Elders Survey Study of Older Cancer Patients
Status: Enrolling
Updated: 10/1/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer
The Vulnerable Elders Survey Study of Older Cancer Patients
Status: Enrolling
Updated:  10/1/2015
UH-Chagrin Highlands
mi
from
Orange Village, OH
Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer
The Vulnerable Elders Survey Study of Older Cancer Patients
Status: Enrolling
Updated: 10/1/2015
UH-Chagrin Highlands
mi
from
Orange Village, OH
Click here to add this to my saved trials
Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer
The Vulnerable Elders Survey Study of Older Cancer Patients
Status: Enrolling
Updated:  10/1/2015
UH-Westlake
mi
from
Westlake, OH
Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer
The Vulnerable Elders Survey Study of Older Cancer Patients
Status: Enrolling
Updated: 10/1/2015
UH-Westlake
mi
from
Westlake, OH
Click here to add this to my saved trials
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults
Status: Enrolling
Updated:  10/1/2015
UCLA Clinical AIDS Research and Education (CARE) Center
mi
from
Los Angeles, CA
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults
Status: Enrolling
Updated: 10/1/2015
UCLA Clinical AIDS Research and Education (CARE) Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults
Status: Enrolling
Updated:  10/1/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults
Status: Enrolling
Updated: 10/1/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults
Status: Enrolling
Updated:  10/1/2015
Boston University Cancer Research Center
mi
from
Boston, MA
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults
Status: Enrolling
Updated: 10/1/2015
Boston University Cancer Research Center
mi
from
Boston, MA
Click here to add this to my saved trials
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults
Status: Enrolling
Updated:  10/1/2015
Laser Surgery Care
mi
from
New York, NY
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults
Status: Enrolling
Updated: 10/1/2015
Laser Surgery Care
mi
from
New York, NY
Click here to add this to my saved trials
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults
Status: Enrolling
Updated:  10/1/2015
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults
Status: Enrolling
Updated: 10/1/2015
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults
Status: Enrolling
Updated:  10/1/2015
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults
Status: Enrolling
Updated: 10/1/2015
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults
Status: Enrolling
Updated:  10/1/2015
Benaroya Research Institute at Virginia Mason Medical Center
mi
from
Seattle, WA
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults
Status: Enrolling
Updated: 10/1/2015
Benaroya Research Institute at Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin
Prevalence of Delayed Nausea and Vomiting in Patients Being Treated With Oxaliplatin-based Regimens (mFOLFOX6 or FOLFOX7) for Colorectal Cancer
Status: Enrolling
Updated:  10/5/2015
Beth Israel Medical Center - Philipps Ambulatory Care Center
mi
from
New York, NY
Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin
Prevalence of Delayed Nausea and Vomiting in Patients Being Treated With Oxaliplatin-based Regimens (mFOLFOX6 or FOLFOX7) for Colorectal Cancer
Status: Enrolling
Updated: 10/5/2015
Beth Israel Medical Center - Philipps Ambulatory Care Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS
Status: Enrolling
Updated:  10/6/2015
Orlando Health
mi
from
Orlando, FL
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS
Status: Enrolling
Updated: 10/6/2015
Orlando Health
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS
Status: Enrolling
Updated:  10/6/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS
Status: Enrolling
Updated: 10/6/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Brief Physician-Initiated Quit Smoking Strategies for Clinical Oncology Settings
Status: Enrolling
Updated:  10/6/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Brief Physician-Initiated Quit Smoking Strategies for Clinical Oncology Settings
Status: Enrolling
Updated: 10/6/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
A Phase II Trial of Oral Thalidomide as an Adjuvant Agent Following Metastasectomy in Patients With Recurrent Colorectal Cancer
Status: Enrolling
Updated:  10/6/2015
Center for Cancer Care at Goshen Health System
mi
from
Goshen, IN
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
A Phase II Trial of Oral Thalidomide as an Adjuvant Agent Following Metastasectomy in Patients With Recurrent Colorectal Cancer
Status: Enrolling
Updated: 10/6/2015
Center for Cancer Care at Goshen Health System
mi
from
Goshen, IN
Click here to add this to my saved trials
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
A Phase II Trial of Oral Thalidomide as an Adjuvant Agent Following Metastasectomy in Patients With Recurrent Colorectal Cancer
Status: Enrolling
Updated:  10/6/2015
Suburban Hospital Cancer Program
mi
from
Bethesda, MD
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
A Phase II Trial of Oral Thalidomide as an Adjuvant Agent Following Metastasectomy in Patients With Recurrent Colorectal Cancer
Status: Enrolling
Updated: 10/6/2015
Suburban Hospital Cancer Program
mi
from
Bethesda, MD
Click here to add this to my saved trials
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
A Phase II Trial of Oral Thalidomide as an Adjuvant Agent Following Metastasectomy in Patients With Recurrent Colorectal Cancer
Status: Enrolling
Updated:  10/6/2015
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
mi
from
Bethesda, MD
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
A Phase II Trial of Oral Thalidomide as an Adjuvant Agent Following Metastasectomy in Patients With Recurrent Colorectal Cancer
Status: Enrolling
Updated: 10/6/2015
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
mi
from
Bethesda, MD
Click here to add this to my saved trials
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
A Phase II Trial of Oral Thalidomide as an Adjuvant Agent Following Metastasectomy in Patients With Recurrent Colorectal Cancer
Status: Enrolling
Updated:  10/6/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
A Phase II Trial of Oral Thalidomide as an Adjuvant Agent Following Metastasectomy in Patients With Recurrent Colorectal Cancer
Status: Enrolling
Updated: 10/6/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
A Phase II Trial of Oral Thalidomide as an Adjuvant Agent Following Metastasectomy in Patients With Recurrent Colorectal Cancer
Status: Enrolling
Updated:  10/6/2015
Charles M. Barrett Cancer Center at University Hospital
mi
from
Cincinnati, OH
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
A Phase II Trial of Oral Thalidomide as an Adjuvant Agent Following Metastasectomy in Patients With Recurrent Colorectal Cancer
Status: Enrolling
Updated: 10/6/2015
Charles M. Barrett Cancer Center at University Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
A Phase II Trial of Oral Thalidomide as an Adjuvant Agent Following Metastasectomy in Patients With Recurrent Colorectal Cancer
Status: Enrolling
Updated:  10/6/2015
UPMC Cancer Center at UPMC Presbyterian
mi
from
Pittsburgh, PA
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
A Phase II Trial of Oral Thalidomide as an Adjuvant Agent Following Metastasectomy in Patients With Recurrent Colorectal Cancer
Status: Enrolling
Updated: 10/6/2015
UPMC Cancer Center at UPMC Presbyterian
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated:  10/7/2015
Cancer Care of Western North Carolina
mi
from
Asheville, NC
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated: 10/7/2015
Cancer Care of Western North Carolina
mi
from
Asheville, NC
Click here to add this to my saved trials
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated:  10/7/2015
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
mi
from
Greensboro, NC
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated: 10/7/2015
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
mi
from
Greensboro, NC
Click here to add this to my saved trials
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated:  10/7/2015
Leo W. Jenkins Cancer Center at ECU Medical School
mi
from
Greenville, NC
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated: 10/7/2015
Leo W. Jenkins Cancer Center at ECU Medical School
mi
from
Greenville, NC
Click here to add this to my saved trials
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated:  10/7/2015
Rex Cancer Center at Rex Hospital
mi
from
Raleigh, NC
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated: 10/7/2015
Rex Cancer Center at Rex Hospital
mi
from
Raleigh, NC
Click here to add this to my saved trials
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated:  10/7/2015
Marion L. Shepard Cancer Center
mi
from
Washington, NC
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab
Status: Enrolling
Updated: 10/7/2015
Marion L. Shepard Cancer Center
mi
from
Washington, NC
Click here to add this to my saved trials
Improving Colon Cancer Screening for Diverse Populations
The CHOICES/"OPCIONES Project: Improving Colon Cancer Screening for Diverse Populations
Status: Enrolling
Updated:  10/8/2015
University of New Mexico
mi
from
Albuquerque, NM
Improving Colon Cancer Screening for Diverse Populations
The CHOICES/"OPCIONES Project: Improving Colon Cancer Screening for Diverse Populations
Status: Enrolling
Updated: 10/8/2015
University of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Improving Colon Cancer Screening for Diverse Populations
The CHOICES/"OPCIONES Project: Improving Colon Cancer Screening for Diverse Populations
Status: Enrolling
Updated:  10/8/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Improving Colon Cancer Screening for Diverse Populations
The CHOICES/"OPCIONES Project: Improving Colon Cancer Screening for Diverse Populations
Status: Enrolling
Updated: 10/8/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Improving Colon Cancer Screening for Diverse Populations
The CHOICES/"OPCIONES Project: Improving Colon Cancer Screening for Diverse Populations
Status: Enrolling
Updated:  10/8/2015
Carolinas Healthcare Systems
mi
from
Charlotte, NC
Improving Colon Cancer Screening for Diverse Populations
The CHOICES/"OPCIONES Project: Improving Colon Cancer Screening for Diverse Populations
Status: Enrolling
Updated: 10/8/2015
Carolinas Healthcare Systems
mi
from
Charlotte, NC
Click here to add this to my saved trials
Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers
Improving the Quality of Advanced Cancer Care With Disease Management
Status: Enrolling
Updated:  10/8/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers
Improving the Quality of Advanced Cancer Care With Disease Management
Status: Enrolling
Updated: 10/8/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Trial of Acupuncture for Reduction of Post-Colectomy Ileus
A Phase II Randomized Controlled Trial of Acupuncture for Reduction of Post-Colectomy Ileus
Status: Enrolling
Updated:  10/9/2015
Memorial Sloan-Kettering Cancer Center 1275 York Avenue
mi
from
New York, NY
Trial of Acupuncture for Reduction of Post-Colectomy Ileus
A Phase II Randomized Controlled Trial of Acupuncture for Reduction of Post-Colectomy Ileus
Status: Enrolling
Updated: 10/9/2015
Memorial Sloan-Kettering Cancer Center 1275 York Avenue
mi
from
New York, NY
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer
A Phase II Study of Active Immunotherapy With PANVAC or Autologous, Cultured Dendritic Cells Infected With PANVAC After Complete Resection of Hepatic or Pulmonary Metastases of Colorectal Carcinoma
Status: Enrolling
Updated:  10/11/2015
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington,
Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer
A Phase II Study of Active Immunotherapy With PANVAC or Autologous, Cultured Dendritic Cells Infected With PANVAC After Complete Resection of Hepatic or Pulmonary Metastases of Colorectal Carcinoma
Status: Enrolling
Updated: 10/11/2015
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer
A Phase II Study of Active Immunotherapy With PANVAC or Autologous, Cultured Dendritic Cells Infected With PANVAC After Complete Resection of Hepatic or Pulmonary Metastases of Colorectal Carcinoma
Status: Enrolling
Updated:  10/11/2015
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer
A Phase II Study of Active Immunotherapy With PANVAC or Autologous, Cultured Dendritic Cells Infected With PANVAC After Complete Resection of Hepatic or Pulmonary Metastases of Colorectal Carcinoma
Status: Enrolling
Updated: 10/11/2015
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials